ライフサイエンスコーパス: MMC

1 MMC had no effect on acquisition of HSV-2 during 72 mont

2 MMC is irreversible at term.

3 MMC is passively transported and bioreductively activate

4 MMC outperforms ART significantly in cost per infection

5 MMC therapy is a potent inducer of PVOD in humans and ra

6 MMC, although still off-label treatment for ophthalmic s

7 MMC-induced PVOD in rats represents a unique model to te

8 10 years ago: group 1, intraoperative 0.02% MMC for 5 minutes; group 2, LCAU.

9 yes treated with surface ablation with 0.02% MMC were compared with nontreated eyes at Vissum Santa H

10 ased locomotor activity was observed after 4-MMC administration in both strains with significantly mo

11 ese results show that the cathinone analog 4-MMC exhibits thermoregulatory and locomotor properties t

12 uction of body temperature was produced by 4-MMC in Wistar rats at 23 degrees C or 27 degrees C with

13 he determination of cathinone derivatives (4-MMC and 4-MEC) in three seized street samples that are i

14 locomotor stimulation produced by 10 mg/kg 4-MMC was nearly identical to that produced by 1 mg/kg d-m

15 The drug 4-methylmethcathinone (4-MMC; aka, mephedrone, MMCAT, "plant food", "bath salts")

16 vatives mephedrone (4-methylmethcathinone; 4-MMC) and 4'-methyl-N-ethylcathinone (4-methylethcathinon

17 tored after subcutaneous administration of 4-MMC (1-10 mg/kg ) using an implantable radiotelemetry sy

18 thermoregulatory and locomotor effects of 4-MMC.

19 nd the fellow eyes in both groups (P = 0.926 MMC, P = 0.468 LCAU).

20 ation of DNA-modified electrode in activated MMC led to alterations in DNA and changes in its electro

21 Additionally, MMC is a potent bactericide for a broad range of bacteri

22 omplete success rates compared to adjunctive MMC; however, the risk of persistent hypotony is higher

23 n vitro binding activity was confirmed after MMC conjugation.

24 or in combination with DNA damaging agents (MMC or oxaliplatin) in PDA cell lines that are either DN

25 In addition, although MMC females laid significantly more eggs than polyandrou

26 An MMC conjugate (MMC-TOC) was synthesized on solid-phase a

27 d endothelial cell density (ECD) reported an MMC-related decrease in ECD, no clinical adverse outcome

28 atients (3.1-20.4 years of age) underwent an MMC-augmented primary trabeculectomy during the period f

29 s was reduced 5.8 and 3.8 mm Hg in AgNP- and MMC-treated eyes, respectively.

30 P was reduced 4.1 and 0.2 mm Hg in AgNP- and MMC-treated eyes, respectively.

31 eriods: prior to the availability of ART and MMC (1999-2004), during early availability of ART and MM

32 -2004), during early availability of ART and MMC (2004-2007), and during mature program scale-up (200

33 l Rakai communities, community-level ART and MMC coverage, sociodemographics, sexual behaviors, and H

34 lysis were 100% and 94.4% in bevacizumab and MMC groups, respectively (P = .32, log-rank test).

35 lymphoblasts were hypersensitive to MMC and MMC-induced monoubiquitination of FANCD2 was impaired.

36 tentially achievable by price reductions and MMC interventions targeting F&V intake in the US populat

37 lig4 double mutants toward high salinity and MMC treatments, indicated the involvement of NHEJ-mediat

38 da knockout mutants toward high salinity and MMC treatments, with higher levels of accumulation of do

39 ent of NHEJ-mediated repair of salinity- and MMC-induced DSBs.

40 , and in increased levels of spontaneous and MMC-induced chromatid breaks.

41 hea, unlike in skin and intestine, CTMCs and MMCs both express all six serine proteases and CPA3 (mMC

42 We applied MMC to both human and yeast datasets and show it is bett

43 As MMC does not inherently possess any anti-cancer activity

44 deficient RecN(K35A) binds and forms foci at MMC-induced DSBs, but is not released from the MMC-induc

45 is denied differences in bleb height between MMC vs OLO (140.5 +/- 20.3 mu vs 129.2 +/- 19.3 mu respe

46 in mitochondrial gene expression induced by MMC treatment.

47 amage and cell cycle perturbation induced by MMC, suggesting an early role for Blm.

48 his study to identify DNA damages induced by MMC.

49 ation following cell cycle arrest induced by MMC.

50 ending, the $5 billion in savings offered by MMC and ART over TasP in the next decade, for similar he

51 implant) or trabeculectomy with mitomycin C (MMC 0.4 mg/mL for 4 minutes).

52 raftment potential of HSPC, and Mitomycin C (MMC) -sensitive hematopoiesis), were absent in Rad18(-/-

53 ncluding the crosslinking agent mitomycin C (MMC) and the replication inhibitor hydroxyurea, but not

54 Ten eyes received mitomycin C (MMC) and triamcinolone.

55 Experience with mitomycin C (MMC) application during corneal surface ablation procedu

56 e FDA-approved anti-cancer drug mitomycin C (MMC) eradicates persister cells through a growth-indepen

57 o underwent trabeculectomy with mitomycin C (MMC) for uncontrolled elevated intraocular pressure (IOP

58 s were used in 400 cases (93%): mitomycin C (MMC) in 271 (63%), 5-fluorouracil (5-FU) in 129 (30%), a

59 surgery to trabeculectomy with mitomycin C (MMC) in eyes with previous cataract and/or failed glauco

60 Mitomycin C (MMC) is a commonly used and extensively studied chemothe

61 Trabeculectomy with mitomycin C (MMC) is a major treatment option, although both chronic

62 Rad54(-/-) cells rescued their mitomycin C (MMC) sensitivity, and decreased both the level of DNA da

63 ivity to the DNA damaging agent mitomycin C (MMC) that correlates with delayed repair of MMC-induced

64 y on accurate concentrations of mitomycin C (MMC) to prevent scarring with trabeculectomy surgery.

65 in microstent implantation with mitomycin C (MMC) versus trabeculectomy with MMC.

66 creased cellular sensitivity to mitomycin C (MMC), and in increased levels of spontaneous and MMC-ind

67 tivity to crosslinkers, such as mitomycin C (MMC), we find that they are largely resistant to HU, exc

68 ayed higher levels of basal and mitomycin C (MMC)-induced chromosomal abnormalities.

69 , but is deficient in repair of mitomycin C (MMC)-induced DNA damage.

70 Moreover, repair of mitomycin C (MMC)-induced DSBs and sister chromatid exchanges (SCEs),

71 ation by the ICL-inducing agent mitomycin C (MMC).

72 and the DNA cross-linking agent mitomycin C (MMC).

73 ) procedure with application of mitomycin C (MMC).

74 rand crosslinks (ICLs), such as mitomycin C (MMC).

75 to the DNA cross-linking agent mitomycin C (MMC).

76 h European-derived race; use of mitomycin C (MMC); higher concentrations of MMC, when used; and highe

77 ot BLM, conferred resistance to mitomycin C (MMC, an interstrand crosslinker) and camptothecin (CPT,

78 Mitomycin-C (MMC) and balanced saline solution (BSS) treatment acted

79 OLO) versus trabeculectomy plus mitomycin-C (MMC) show contradictory results.

80 s of 7 cases of PVOD induced by mitomycin-C (MMC) therapy from the French Pulmonary Hypertension Regi

81 ication and trabeculectomy with mitomycin-C (MMC) vs. Collagen Matrix (CM).

82 mplant) or trabeculectomy with mitomycin C ([MMC]; 0.4 mg/mL for 4 minutes).

83 We calculated MMC concentration using a calibration curve (range, 0.3-

84 enarios: (a) a national mass media campaign (MMC) aimed to increase consumption of F&Vs and reduce co

85 Both mass media campaigns (MMCs) and economic incentives may increase F&V consumpti

86 rites contain abiotic macromolecular carbon (MMC) phases detected in association with small oxide gra

87 Magnetic micro-carriers (MMCs) were functionalized with molecular beacons to enab

88 ed sterility, altered Megaspore Mother Cell (MMC) specification, and delayed programmed cell death in

89 tophagy within 1 h in mouse mesangial cells (MMC) as determined by increased microtubule-associated p

90 ific siRNA in primary mouse mesangial cells (MMC), resulted in increased protein levels of type I col

91 l as TGF-beta-treated mouse mesangial cells (MMC).

92 ta-treated mouse glomerular mesangial cells (MMCs).

93 CCR2(+) activated myeloid mononuclear cells (MMCs) and the levels of proinflammatory cytokines in the

94 omatal stem cells (meristemoid mother cells [MMCs]) are fundamental for the generation and patterning

95 ents, we designed a multimodality chelation (MMC) scaffold which combined a radiometal chelating agen

96 ing approach with a multimodality chelation (MMC) scaffold would minimize steric effects of dye conju

97 tion in the number of multiple motile cilia (MMC) covering the cell surface.

98 month efficacy of medical male circumcision (MMC) against herpes simplex virus 2 (HSV-2) incidence am

99 Medical male circumcision (MMC) and antiretroviral therapy (ART) are proven HIV pre

100 asing coverage of medical male circumcision (MMC) and antiretroviral treatment (ART) at CD4 <350/muL.

101 oexpression called mixed model coexpression (MMC), which models coexpression within a mixed model fra

102 of dorsally projecting medial motor column (MMC) neurons.

103 Community MMC coverage in males and ART coverage in HIV-positive p

104 Among males, each 10% increase in community MMC coverage was associated with an adjusted IRR of 0.87

105 In Rakai, Uganda, increasing community MMC and female ART coverage was associated with lower co

106 Median community MMC coverage increased from 19% to 39%, and median commu

107 ccur as part of the migrating motor complex (MMC), a contractility pattern of the gastrointestinal tr

108 ation accuracy and variability of compounded MMC are unknown.

109 The resulting compounds, MMC(IR800)-TOC and DA(IR800)-TOC, were labeled with Cu a

110 or metal with minimum metallic conductivity (MMC).

111 ase 1 phosphorylation nevertheless conferred MMC hypersensitivity.

112 An MMC conjugate (MMC-TOC) was synthesized on solid-phase and compared wit

113 g limbo-keratoplasty with conjunctivoplasty, MMC, and AM transplantation is a promising new surgical

114 lasty in conjunction with conjunctivoplasty, MMC, and AM.

115 tire life and experiencing many copulations (MMC); and polyandrous females with a different male over

116 in baseline diets, CVD rates, MMC coverage, MMC duration, and declining effects over time.

117 plus Ag and TLR-induced activation of CTMCs, MMCs, and BMMCs and found that SHIP delays the maturatio

118 Cu-MMC(IR800)-TOC demonstrated higher potency for cyclic ad

119 th octreotide reduced tumor uptake of (64)Cu-MMC(IR800)-TOC by 66%.

120 dies revealed higher tumor uptake for (64)Cu-MMC(IR800)-TOC than (64)Cu-DA(IR800)-TOC (5.2 +/- 0.2 vs

121 caused a dose-dependent reduction in (64)Cu-MMC(IR800)-TOC uptake whereas (64)Cu-DA(IR800)-TOC was n

122 Excretion of (64)Cu-MMC(IR800)-TOC was primarily through the liver and splee

123 Three dye-derivatized MMC compounds were synthesized and radiolabeled.

124 (range, 0.3-0.5 mg/mL) generated by dividing MMC peak area by internal standard peak area and plottin

125 cy of OLO as adjuvant compared to low-dosage MMC in trabeculectomy.

126 tm(-/-) single mutant mice survived low-dose MMC similar to wild-type controls, Hus1(neo/neo)Atm(-/-)

127 Acid and electroreductive MMC activations were compared and different adducts were

128 nuclear core complex proteins, (4) elevated MMC-induced chromosome aberrations, and (5) sensitivity

129 fective HIV prevention strategy is to expand MMC coverage and then scale up ART, but the most cost-ef

130 We find MMC effectively eradicates cells grown in numerous diffe

131 robust Fancd2 mono-ubiquitination following MMC treatment.

132 ommon compounding and storage techniques for MMC resulted in a lower accuracy and wider range of conc

133 ignificantly longer for MOC females than for MMC or PMC females.

134 should be tested as a preventive therapy for MMC-induced PVOD in humans.

135 ols and was not significantly different from MMC.

136 Therefore, RT + FU/MMC remains the preferred standard of care.

137 and OS were statistically better for RT + FU/MMC versus RT + FU/CDDP (5-year DFS, 67.8% v 57.8%; P =

138 CCR with FU/MMC has a statistically significant, clinically meaningf

139 (188 +/- 47 mum, P = 0.285) compared with GS+MMC (109 +/- 26 mum, P = 0.023 to GS) and PS+MMC (48 +/-

140 ng that high ART coverage combined with high MMC coverage provides approximately the same HIV inciden

141 he mean preoperative IOP was 26.7(+/-5.2) in MMC and 27.3(+/-6.0) in OLO eyes.

142 0.0005) from 2.5 (+/-0.3) to 1.2 (+/-0.4) in MMC and from 2.6 (+/-0.2) to 1.4 (+/-0.3) in OLO group,

143 at the </=15 mm Hg target IOP 35% and 45% in MMC and OLO, respectively.

144 ptosis upon knockdown of LC3 by siRNA and in MMC from LC3 null (LC3(-/-)) mice.

145 lso show that TGF-beta1 induces autophagy in MMC via TAK1-MKK3-p38 signaling pathway.

146 nce after incubation of the DNA-biosensor in MMC solution for a known time was used as indication of

147 e of 15.2 (+/-3.2) and 15.8 (+/-2.3) mmHg in MMC and OLO, respectively.

148 FOG2 knockdown by siRNAs in MMC activated Akt and increased the protein content/cell

149 Variability in MMC concentration could cause inconsistency in glaucoma

150 educed central and peripheral vascularity in MMC group (P = 0.027; P = 0.041).

151 study showed similar trends of regulation in MMCs treated with HG or TGF-beta.

152 rms of cytokine production, we found that in MMCs and BMMCs, which are poor producers of TLR-induced

153 so by influencing the polarity of individual MMCs.

154 phenotype of constitutive CTMCs and induced MMCs in trachea and large airways in antigen-sensitized

155 in the proximal bronchi, whereas the induced MMCs express only four proteases, mMCP-1, -2, -6, and -7

156 graft was more effective than intraoperative MMC in minimizing pterygium recurrence at the 10-year fo

157 y pterygium were treated with intraoperative MMC (n = 63) or LCAU transplants (n = 52).

158 Treatment with intraoperative MMC was not associated with long-term corneal endothelia

159 2 (HSV-2) incidence among men in the Kisumu MMC randomized trial.

160 enes was screened in a mouse mast cell line, MMC-1.

161 tion in the inter-sample correlation matrix, MMC is able to produce gene coexpressions that are not i

162 MCP-4(+)-7(+), and CPA3(+)) and mucosal MCs (MMCs) (mMCP-1(+) and 2(+)).

163 The measured MMC concentration determined using the high-performance

164 (CCR) with fluorouracil (FU) plus mitomycin (MMC) decreased colostomy failure (CF) when compared with

165 ole in connective tissue (CTMCs) or mucosal (MMCs) mast cells.

166 Myelomeningocele (MMC) is a devastating spinal cord birth defect, which re

167 across US adults from 2015 to 2030: national MMCs and national F&V price reductions of 10% and 30%.

168 equitable proportional effects.Both national MMCs and price-reduction policies could reduce US CVD mo

169 Neither MMC nor male ART coverage was associated with lower fema

170 ents in which multiple copulations occurred, MMC and PMC, had offspring with significantly higher egg

171 Addition of MMC to an in vitro translation reaction significantly de

172 dothelial counts after the administration of MMC during surgery, the clinical significance of this fi

173 In rats, intraperitoneal administration of MMC induced PVOD, as demonstrated by pulmonary hypertens

174 substantiating the clinical applicability of MMC against bacterial infections.

175 al outcomes of using PRK with application of MMC for enhancement were good.

176 mitomycin C (MMC); higher concentrations of MMC, when used; and higher preoperative IOP.

177 Amifostine prevented the development of MMC-induced PVOD in rats.

178 ere is good evidence of the effectiveness of MMC when used intraoperatively as prophylaxis against ha

179 We also demonstrate the efficacy of MMC in an animal model and a wound model, substantiating

180 odeling was used to estimate the efficacy of MMC on HSV-2 risk.

181 vivo studies demonstrating the formation of MMC-DNA adducts, we chose to investigate alternative nuc

182 A significant fraction of MMC sensitivity is independent of the Fanconi anaemia pa

183 The interaction of MMC with ribosomal RNA and subsequent inhibition of prot

184 Measurement of MMC using the high-performance liquid chromatography met

185 We acquired 60 samples of 0.4 mg/mL of MMC from a spectrum of common compounding and storage te

186 New findings regarding the penetration of MMC to the endothelium and into the aqueous humor may le

187 stions about the long-term safety profile of MMC, especially with regard to decreased keratocyte and

188 , mechanism of action, and safety profile of MMC.

189 r, regarding the long-term safety profile of MMC.

190 The pathological progression of MMC involves failure in neural tube and vertebral arch c

191 understanding of pathological progression of MMC is mandatory for appropriate treatment to be rendere

192 rect monitoring of anti-cancer properties of MMC.

193 (MMC) that correlates with delayed repair of MMC-induced chromosomal DNA damage monitored by pulsed-f

194 surveyed in this report support the role of MMC as an adjunctive treatment in surface ablation proce

195 r, its effect is less prominent than that of MMC.

196 Transfection of MMC with miR-200b/c mimics significantly decreased the e

197 offer an appealing approach for treatment of MMC.

198 here, this would support further scale-up of MMC and ART for HIV prevention in sub-Saharan Africa.

199 Over the past 15 years, the use of MMC during surgery in surface ablation has become widesp

200 The use of MMC has revitalized the application of surface ablation

201 Thus, the T-cell-dependent induction of MMCs in trachea, large bronchi, and small intestine prov

202 rrent topical application of either AgNPs or MMC was performed on 14 pigmented Dutch Belted rabbits.

203 al cancer and were treated with MMC alone or MMC plus 5-fluoruracil.

204 ay result from compounding techniques and/or MMC degradation.

205 als in FANCB-deleted cells exposed to CPT or MMC, respectively.

206 welve of 47 patients (25.5%) in the original MMC group and 2 of 29 patients (6.9%) in the LCAU group

207 Amifostine prevents MMC-induced PVOD in rats and should be tested as a preve

208 MMC (109 +/- 26 mum, P = 0.023 to GS) and PS+MMC (48 +/- 30 mum, P = 0.028 to PS).

209 We used pure MMC (Medisca Inc) to generate calibration curves and sul

210 or differences in baseline diets, CVD rates, MMC coverage, MMC duration, and declining effects over t

211 In rats, MMC administration was associated with dose-dependent de

212 us ortholog of CCNO also resulted in reduced MMC and centriole numbers in embryonic epidermal cells.

213 inking an inherited human disease to reduced MMC generation due to a defect in centriole amplificatio

214 s of the opposite sex based on self-reported MMC status and ART use.

215 TGF-beta1 failed to rescue MMC from serum deprivation-induced apoptosis upon knockd

216 er, our data indicate that TGF-beta1 rescues MMC from serum deprivation-induced apoptosis via inducti

217 Due to a lack of evidence for significant MMC activation in the nucleus and for in vivo studies de

218 polis algorithm with Monte Carlo simulation (MMC) was used for analysis of the data.

219 tment strategies including NSAIDs, steroids, MMC and corneal transplants have shown tremendous succes

220 /neo)Atm(-/-) double mutants showed striking MMC hypersensitivity, consistent with a model in which M

221 ial cell adhesion molecule (EpCAM) targeting MMC-immunoconjugate was prepared and dual-labeled with (

222 rrosive nature, the Mg(CB11H12)2/tetraglyme (MMC/G4) electrolyte system permits standardized methods

223 marks but it is far less cost effective than MMC and ART.

224 NP-treated eyes showed more lymphocytes than MMC-treated eyes.

225 of adult offspring were higher for PMC than MMC females, showing that polyandrous mating enhances th

226 We also demonstrate that MMC-induced chromosomal anomalies are increased in SNM1B

227 l-shift and binding assays demonstrated that MMC rapidly decreased the transcript levels of 18S ribos

228 It was found that MMC did not interact with DNA.

229 ll proliferation and apoptosis revealed that MMC treatment caused severe damage in highly replicating

230 Experience has shown that MMC is highly effective at preventing haze and is well t

231 ngs and gastrointestinal motility during the MMC is largely unknown, however, as is its ability to st

232 The mean follow-up times for the MMC and bevacizumab groups were 7.8 +/- 2.2 months and 7

233 C-induced DSBs, but is not released from the MMC-induced DNA lesions, resulting in a defect in homolo

234 1.0 medications (p = 0.63) at 2 years in the MMC and CM groups, respectively.

235 follow-up period was 138 +/- 2 months in the MMC group and 137 +/- 2 months in the LCAU group.

236 ar blebs without oozing were recorded in the MMC group and 2 (10%) in the OLO group, without intergro

237 an ECD was 2,39 2 +/- 342 cells/mm(2) in the MMC group and 2,390 +/- 388 cells/mm(2) in the LCAU grou

238 The mean preoperative IOP in the MMC group improved from 23.3 +/- 4.9 mm Hg with 2.6 +/-

239 ent study, 76 of the 114 patients (47 in the MMC group, 29 in the LCAU group) were contacted, whereas

240 rrent 10-year long-term follow-up (47 in the MMC group, 29 in the LCAU group).

241 hinning or avascularity that was seen in the MMC treatment group.

242 ormance liquid chromatography to measure the MMC concentration of all samples.

243 Neither the MMC nor the individual national economic policies would

244 s is warranted as well as application of the MMC dual labeling approach with other monoclonal antibod

245 d receptor pharmacology and suggest that the MMC scaffold is a useful tool for the development of dua

246 aline phosphatase was then conjugated to the MMC surface through biotin-streptavidin interactions.

247 can produce biotin-modified sequences on the MMCs.

248 ted with TNF inhibitors at the time of their MMC-augmented primary trabeculectomy.

249 Therefore, MMC is the first broad-spectrum compound capable of elim

250 rgery, AgNPs are a reasonable alternative to MMC as adjunctive therapy.

251 Compared to MMC, AgNPs result in an improved and sustained reduction

252 ate fragmented chromosomes after exposure to MMC.

253 airing DNA damage resulting from exposure to MMC.

254 Their lymphoblasts were hypersensitive to MMC and MMC-induced monoubiquitination of FANCD2 was imp

255 ctors, including FANCD2, BRCA1 and RAD51, to MMC-induced subnuclear foci.

256 beculectomy (10 eyes) and were randomized to MMC or CM.

257 wild-type FANCM improved their resistance to MMC re-establishing FANCD2 monoubiquitination.

258 e role of the 9-1-1 complex in responding to MMC was partially ATR-independent, as a HUS1 mutant that

259 romosome aberrations, and (5) sensitivity to MMC and camptothecin.

260 and long-term success rates quite similar to MMC, with at least equivalent safety.

261 Topical MMC and interferon alpha-2b are an effective treatment m

262 patients treated consecutively with topical MMC (0.4 mg/mL), interferon alpha-2b (1 million units/mL

263 iabetic mouse glomeruli and TGF-beta-treated MMC.

264 -mortality reduction strategy is to scale up MMC and ART jointly.

265 When MMC is applied in the appropriate concentration and conf

266 ensitivity, consistent with a model in which MMC exposure in the context of Hus1 dysfunction results

267 both groups at 24 months: 38.4 +/- 7.6% with MMC and 56.2 +/- 7.9% with CM (mean +/- standard error,

268 population soon after surface ablation with MMC, with a decrease in the stromal bed compensated init

269 omatic hydrocarbons were detected along with MMC phases in Dar al Gani 476.

270 , and 1,102 healthy women, was analyzed with MMC algorithm and cross validation to identify an optima

271 tric trabeculectomy technique augmented with MMC is an effective procedure in the management of glauc

272 Comparing communities with MMC coverage more than 40% (mean male community incidenc

273 e risk of persistent hypotony is higher with MMC.

274 etween standalone ab interno microstent with MMC and trabeculectomy with MMC.

275 due to persistent hypotony was observed with MMC (p = 0.002).

276 This effect is not observed with MMC treatment, suggesting a non-canonical function for t

277 tion, same-site trabeculectomy revision with MMC should be considered as a viable option to achieve r

278 ), and 18 eyes underwent trabeculectomy with MMC (0.02% for 3 minutes).

279 d in patients undergoing trabeculectomy with MMC and in those undergoing Baerveldt implantation durin

280 Tube-shunt surgery and trabeculectomy with MMC are both viable surgical options for managing glauco

281 success rate compared to trabeculectomy with MMC during 5 years of follow-up in the TVT Study.

282 laucoma medications than trabeculectomy with MMC during the first 2 years of the study, but medical t

283 higher success rate than trabeculectomy with MMC during the first 3 years of follow-up.

284 Trabeculectomy with MMC had higher rates of surgical failure and reoperation

285 ts (40 eyes) assigned to trabeculectomy with MMC or Ologen.

286 h tube-shunt surgery and trabeculectomy with MMC produced intraocular pressure (IOP) reduction to the

287 were more frequent after trabeculectomy with MMC relative to tube-shunt surgery, but both procedures

288 ed more frequently after trabeculectomy with MMC than tube shunt placement.

289 ons was higher following trabeculectomy with MMC than tube shunt surgery.

290 microstent with MMC and trabeculectomy with MMC.

291 ldt glaucoma implant) or trabeculectomy with MMC.

292 mitomycin C (MMC) versus trabeculectomy with MMC.

293 d squamous anal cancer and were treated with MMC alone or MMC plus 5-fluoruracil.

294 ompared with previous topical treatment with MMC (with or without surgery; 29.6 +/- 4.7 months; P = .

295 After treatment with MMC, reduced phosphorylation of the ATR substrate CHK1 o

296 iversal Hugoniot of fluid metals (UHFM) with MMC at sufficiently extreme pressures and temperatures.

297 riod, stratified by age, sex, and race.A 1-y MMC in 2015 would increase the average national F&V cons

298 A 1-y MMC would be 35% less effective in preventing CVD deaths

299 25,800 (95% UI 24,300-28,500) DPPs for a 1-y MMC, or the approximately 31,000 (95% UI 26,800-35,300)

300 With a 15-y MMC, increased F&V consumption would be sustained, yield